Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 15, 2022, at 8:30 a.m. (ET) to discuss fourth quarter and full year 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live event on the Zoetis website, with a replay available later that day. Zoetis, a leading animal health company, generated $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on innovation in animal care.
Zoetis Inc. (NYSE:ZTS) has announced a $3.5 billion share repurchase program to enhance shareholder value, extending over multiple years and potentially cancellable. This follows the completion of a previous $2.0 billion buyback program set for 2022. Additionally, the company declared a $0.325 per share dividend for Q1 2022, marking a 30% increase from 2021. These actions reflect Zoetis' strong financial performance and commitment to returning capital to shareholders.
Summary not available.
Zoetis reported a strong financial performance for Q3 2021, with revenue of $2.0 billion, an 11% increase year-over-year, and net income of $552 million, up 15%. Adjusted net income rose to $597 million, or $1.25 per diluted share, marking a 14% increase. The company is optimistic, raising its full-year revenue guidance to $7.700 - $7.750 billion and diluted EPS to $4.23 - $4.29. Key growth drivers included strong sales in petcare products and new monoclonal antibodies, despite facing challenges in livestock product sales.
Zoetis Inc. (NYSE:ZTS) announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development effective January 1, 2022. He succeeds Dr. Catherine Knupp, who plans to retire after leading Zoetis' R&D efforts since the company's inception in 2013. Under her guidance, Zoetis launched over 1,100 new products in five years and established a strong portfolio in animal health. Polzer, previously Senior VP of Global Therapeutics, brings over 20 years of R&D experience and aims to drive continuous innovation in Zoetis' diverse product pipeline.
Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2021 dividend of $0.25 per share, payable on December 1, 2021, to stockholders on record as of October 29, 2021. As a leader in animal health, Zoetis generated revenue of $6.7 billion in 2020, supported by a workforce of approximately 11,300 employees. The company focuses on advancing animal care through innovations in medicines, vaccines, and diagnostics globally.
Zoetis Inc (NYSE:ZTS) will host a webcast on November 4, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and address questions from analysts. Interested parties can access the live webcast on the Zoetis investor relations website. A replay will be available after the event. Zoetis generated $6.7 billion in revenue in 2020 and has a strong portfolio of animal health products.
Zoetis has been recognized for the eighth consecutive year as one of Seramount’s 100 Best Companies, underscoring its commitment to family-friendly benefits and flexible work arrangements. Notably, Kristy Earley-Murray was named Working Mother of the Year, and Chip Dorsey is the first recipient of Working Father of the Year. These honors highlight Zoetis' dedication to supporting working parents, particularly during the ongoing challenges posed by the COVID-19 pandemic, as stated by Executive VP Roxanne Lagano.
Zoetis (NYSE:ZTS) will participate in the Jefferies Virtual Pet Care Summit on September 16, 2021. Executive Vice President Glenn David will represent the company during the presentation at 11:00 a.m. ET. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations. A replay will be available afterward. Zoetis, a leader in animal health, generated $6.7 billion in revenue in 2020, employs approximately 11,300 individuals, and operates in over 100 countries.
Zoetis reported a strong Q2 2021, with revenue of $1.9 billion, a 26% increase year-over-year, and net income up 36% to $512 million. Adjusted net income rose 33% to $566 million ($1.19 per share). U.S. revenue grew 22%, driven by a 34% rise in companion animal products, while international sales surged 31%. The company raised its full-year guidance, projecting revenue between $7.625 billion and $7.700 billion, reflecting strong growth drivers despite expectations of modest growth in H2 2021.